Ali Alyahawi, Ali Alkaf, Rashad Alnamer, Taha Alnosary
2018 Universal Journal of Pharmaceutical Research  
Carbapenem resistance is a major and a future public health problem globally. It occurs mainly among Gram-negative bacteria. Meropenem is the recently marketed carbapenem drug in Yemen. However, recent emergence of carbapenem-resistant isolates has become a major healthcare concern. The current study was designed to estimate the prevalence of meropenem resistance among hospitalised patients in Sana'a, Yemen. The study was performed at a local hospital in Sana'a, Yemen. The records of Meropenem
more » ... usceptibility were taken for hospitalised patients. A total of 443 Meropenem susceptibility samples were collected from August, 2017 to July, 2018. The meropenem susceptibility was studied against several isolated pathogens. Out of 443 study sample, 316 (71.3%) were meropenem sensitive isolates and 25.3% of samples were resistant. The Escherichia coli isolates were observed in 27.5% of sample, followed by Pseudomonas aeruginosa (19.6%). 36.4% of total meropenem sensitive isolates (115/316) were Escherichia coli. In addition, 94.3% (115/122) of Escherichia coli isolates were meropenem sensitive. However, the Klebsiella species had higher meropenem resistance than other pathogens (30/112; 26.8%). Moreover, 89.7% (26/29) of Acinetobacter species isolates were meropenem resistant. 82.4% (42/51) of Klebsiella pneumonia isolates were meropenem sensitive and 32.2% (28/87) of Pseudomonas aeruginosa were meropenem resistance. In the present study, 34.5% (109/316) of meropenem sensitive isolates were from blood cultures, followed by sputum cultures (23.7%; 75/316). However, 58% (65/112) of sputum culture isolates were meropenem resistance. This study concluded that the percentage of resistance to meropenem was high (25.3%) and cannot be neglected. Continued surveillance to closely monitor trends as well as infection control and antibiotic stewardship activities are necessary to preserve treatment options. A more careful monitoring for use of broad-spectrum antibiotics should be instituted.
doi:10.22270/ujpr.v3i5.203 fatcat:ix2jmp7ypzajvkoxfzxxg5yfcy